Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

Summary

The purpose of this study is to estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC and to determine the safety of SPI-1620 when administered in combination with docetaxel.

Timeline

Start

2013-05

Primary completion

2015-07

Completion

2015-07

Outcome

Outcome not reported

Stopped (Enrollment): “The study did not meet efficacy end point and did not enroll patients in the randomized phase.”

Drugs

Indications